Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1/L1 Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07589049
What this trial is testing

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University 42
Testing effectiveness (Phase 2)Looking for participantsNCT05944237
What this trial is testing

HTL0039732 in Participants With Advanced Solid Tumours

Who this might be right for
NeoplasmsProstatic Neoplasms, Castration-ResistantStomach Neoplasms+11 more
Cancer Research UK 150
Testing effectiveness (Phase 2)Looking for participantsNCT05751798
What this trial is testing

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Solid Advanced TumorLymphomaNSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics 41
Testing effectiveness (Phase 2)Ended earlyNCT03737123
What this trial is testing

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Nabil Adra 6
Not applicableStudy completedNCT03305380
What this trial is testing

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Who this might be right for
Stage IV Non-small Cell Lung Cancer
Maastricht Radiation Oncology 637
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Looking for participantsNCT06941857
What this trial is testing

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Testing effectiveness (Phase 2)Looking for participantsNCT05361174
What this trial is testing

Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Who this might be right for
Unresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung Cancer+1 more
Iovance Biotherapeutics, Inc. 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07014215
What this trial is testing

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Resistance to Immunotherapy
Anhui Provincial Cancer Hospital 52
Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Who this might be right for
Breast Cancer
AstraZeneca 625
Large-scale testing (Phase 3)Active Not RecruitingNCT06635824
What this trial is testing

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Who this might be right for
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab 191
Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT03989362
What this trial is testing

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Who this might be right for
Cancer
Jounce Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT06773910
What this trial is testing

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Who this might be right for
Limited Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC 250
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Testing effectiveness (Phase 2)Looking for participantsNCT07501351
What this trial is testing

Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line

Who this might be right for
Hepatocellulcar Carcinoma
Sun Yat-sen University 80
Testing effectiveness (Phase 2)Ended earlyNCT02546986
What this trial is testing

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 100
Next Page